In addition, we show that NFKBIE mutations confer resistance to the BTK inhibitor ibrutinib in the murine models and are associated with inferior outcomes to ibrutinib treatment in CLL patients. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.